Barclays
FLNA

Barclays’s Filana Therapeutics FLNA Stock Holding History

Barclays’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.6K Sell
42,379
-6,083
-13% -$12.5K ﹤0.01% 4173
2025
Q4 		$96K Buy
48,462
+48,371
+53,155% +$155K ﹤0.01% 4592
2025
Q3 		$265 Sell
91
-2,643
-97% -$6.08K ﹤0.01% 5234
2025
Q2 		$4.95K Sell
2,734
-41,396
-94% -$73.7K ﹤0.01% 4974
2025
Q1 		$66.2K Sell
44,130
-49,449
-53% -$125K ﹤0.01% 4535
2024
Q4 		$221K Buy
93,579
+18,832
+25% +$331K ﹤0.01% 4260
2024
Q3 		$2.2M Buy
74,747
+53,487
+252% +$1.23M ﹤0.01% 2780
2024
Q2 		$263K Sell
21,260
-30,098
-59% -$634K ﹤0.01% 3422
2024
Q1 		$1.04M Sell
51,358
-54,232
-51% -$1.25M ﹤0.01% 3090
2023
Q4 		$2.38M Buy
105,590
+78,888
+295% +$1.67M ﹤0.01% 2775
2023
Q3 		$444K Buy
26,702
+6,711
+34% +$133K ﹤0.01% 2867
2023
Q2 		$490K Sell
19,991
-12,510
-38% -$301K ﹤0.01% 2764
2023
Q1 		$784K Sell
32,501
-11,155
-26% -$309K ﹤0.01% 2920
2022
Q4 		$1.29M Buy
43,656
+22,114
+103% +$795K ﹤0.01% 2593
2022
Q3 		$901K Buy
21,542
+902
+4% +$24.4K ﹤0.01% 2318
2022
Q2 		$581K Sell
20,640
-3,621
-15% -$91.4K ﹤0.01% 2761
2022
Q1 		$901K Sell
24,261
-86,747
-78% -$3.68M ﹤0.01% 2491
2021
Q4 		$4.85M Buy
111,008
+54,207
+95% +$2.84M ﹤0.01% 1730
2021
Q3 		$3.52M Buy
56,801
+51,960
+1,073% +$4.34M ﹤0.01% 1874
2021
Q2 		$414K Sell
4,841
-22,491
-82% -$1.2M ﹤0.01% 3182
2021
Q1 		$1.23M Buy
27,332
+16,718
+158% +$658K ﹤0.01% 2649
2020
Q4 		$72K Sell
10,614
-66
-0.6% -$589 ﹤0.01% 4263
2020
Q3 		$122K Sell
10,680
-18,602
-64% -$83.9K ﹤0.01% 4143
2020
Q2 		$91K Buy
+29,282
New +$133K ﹤0.01% 4583
2013
Q4 		– Sell
-135
Closed -$2K – 7658
2013
Q3 		$2K Sell
135
-7,610
-98% -$133K ﹤0.01% 7205
2013
Q2 		$120K Buy
+7,745
New +$164K ﹤0.01% 5637

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Barclays's FLNA Position: Q1 2026 in Review

Barclays reduced its Filana Therapeutics (FLNA) stake by 13% in Q1 2026, selling an estimated $12.5K and leaving 42,379 shares worth $71.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4173.

Barclays first reported a position in FLNA in Q2 2013 and has held it in 26 quarters since. The position peaked at $4.85M in Q4 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Barclays held 42,379 shares of Filana Therapeutics worth $71.6K as of Q1 2026.
  • Barclays sold 6,083 Filana Therapeutics shares in Q1 2026, an estimated $12.5K.
  • Filana Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4173 holding.
  • Barclays first reported a position in Filana Therapeutics in Q2 2013 and has held it in 26 quarters since.
  • Barclays's Filana Therapeutics position peaked at $4.85M in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.